TY - JOUR
T1 - The microbiome and HLA-B27-associated acute anterior uveitis
AU - Rosenbaum, James T.
AU - Asquith, Mark
N1 - Funding Information:
The work of the authors was supported by NIH Grants EY026572 to J.T.R., and EY029266 to M.A. and J.T.R., the Spondylitis Association of America to M.A., the William and Mary Bauman Foundation to J.T.R., the Stan and Madelle Family Trust to J.T.R., the Rheumatology Research Foundation to J.T.R. and M.A. and Research to Prevent Blindness to J.T.R. The authors wish to acknowledge many valuable contributions made by the research community that were omitted owing to space to constraints.
Publisher Copyright:
© 2018, Springer Nature Limited.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Acute anterior uveitis (AAU) and the spondyloarthritis (SpA) subtypes ankylosing spondylitis, reactive arthritis and psoriatic arthritis are among the inflammatory diseases affected by the biology of the intestinal microbiome. In this Review, the relationship between AAU, SpA and the microbiome is discussed, with a focus on the major SpA risk gene HLA-B*27 and how it is associated with both intestinal tolerance and the loss of ocular immune privilege that can accompany AAU. We provide four potential mechanisms to account for how dysbiosis, barrier function and immune response contribute to the development of ocular inflammation and the pathogenesis of AAU. Finally, potential therapeutic avenues to target the microbiota for the clinical management of AAU and SpA are outlined.
AB - Acute anterior uveitis (AAU) and the spondyloarthritis (SpA) subtypes ankylosing spondylitis, reactive arthritis and psoriatic arthritis are among the inflammatory diseases affected by the biology of the intestinal microbiome. In this Review, the relationship between AAU, SpA and the microbiome is discussed, with a focus on the major SpA risk gene HLA-B*27 and how it is associated with both intestinal tolerance and the loss of ocular immune privilege that can accompany AAU. We provide four potential mechanisms to account for how dysbiosis, barrier function and immune response contribute to the development of ocular inflammation and the pathogenesis of AAU. Finally, potential therapeutic avenues to target the microbiota for the clinical management of AAU and SpA are outlined.
UR - http://www.scopus.com/inward/record.url?scp=85054662451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054662451&partnerID=8YFLogxK
U2 - 10.1038/s41584-018-0097-2
DO - 10.1038/s41584-018-0097-2
M3 - Review article
C2 - 30301938
AN - SCOPUS:85054662451
VL - 14
SP - 704
EP - 713
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
SN - 1759-4790
IS - 12
ER -